Azierta, Azierta Foundation and Paredox Therapeutics partner to expand the clinical development of a novel oncology therapeutic in ovarian cancer

Cambridge, Massachusetts and Madrid, Spain – Paredox Therapeutics, LLC, Azierta Contract Scientific Support Consulting, S.L. and Azierta Foundation, announced today at the European Society for Medical Oncology (ESMO 2019) a partnership for co-development of Paredox’s novel therapeutic (PER-016) targeting mitochondria-based oxidative stress signaling pathways in ovarian cancer.   Azierta Contract Scientific Support Consulting, S.L. is a Science and Health consultancy firm committed to strengthening bonds between science and the business environment through the “Science to Business” concept. Azierta provides services in the field of medicinal products, Medical…